Doriced

INDICATIONS	DOSAGE	FREQUENCY	INFUSION TIME (HOURS)	DURATION
Complicated Intra- abdominal Infections	500 mg	TID	1 Hour	5-14 days
Complicated Urinary Tract Infections	500 mg	TID	1 Hour	10 days Duration can be extended up to 14 days for patients with concurrent bacteremia

Duration includes a possible switch to an appropriate oral therapy, after at least 3 days of parenteral therapy, once clinical improvement has been demonstrated.
In patients218 years of age
E coll, K.pneumoniae, P. aeruginosa, Bacteroides caccae, B. fragilis, B. thetaiotaomicron, B uniformis, B. vulgatus, S. intermedius, S. constellatus and Peptostreptococcus micros
E col including cases with concurrent bacteremia, K. pneumoniae, P. mirabilis, P. aeruginosa and A. baumannii

Daptomycin should be administered intravenously either by injection over a 2 minute period or by infusion over a 30 minute period.

Constitutes the vial with 10 mL of sterile water for injection or 0.9% NaCl and gently shake to form a suspension". The resultant concentration is 50 mg/mL
Withdraw the suspension using a syringe and add it to an infusion bag containing 100 mL of normal saline or 5% dextrose; gently shake until clear. The final infusion solution concentration is 4.5 mg/mL.
Doripenem has a broad spectrum of activity against Gram-positive, Gram-negative and anaerobic bacteria including MDR strains, most notably the ESBL and Amp-C B-lactamase producing Gram-negative organisms.
Doripenem is the higher activity against P. aeruginosa than the rest of Carbapenems, so it is especially useful for severe infections caused by MDR P. aeruginosa.
Doripenem has less seizure potential as it has the lowest GABA receptor binding affinity among the Carbapenems.
Doripenem has longer stability in solution than Imipenem or Meropenem; this allows the drug to be administered for extended infusion durations (4 hours), thus optimizing pharmacokinetic/ pharmacodynamic parameters to target less susceptible pathogens.
Among Carbapenems, Doripenem is more potent against P. aeruginosa than Imipenem and Meropenem, and it exhibits lesser propensity for development of resistant strains.

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents